Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Top Cited Papers
- 1 January 2017
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 18 (1) , 75-87
Abstract
No abstract availableKeywords
Funding Information
- Clovis Oncology
- US Department of Defense Ovarian Cancer Research Program (OC120506)
- V Foundation Translational Award
- Stand Up To Cancer—Ovarian Cancer Research Fund Alliance—National Ovarian Cancer Coalition Dream Team Translational Research Grant (SU2C-AACR-DT16-15)
- Ann Rife Cox Chair in Gynecology
- Judy Reis (Al Pisani) Ovarian Cancer Research Fund (RLC)
- UCH/UCL Biomedical Research Centre (RK)
- Experimental Cancer Medicine Centres at UCL (RK)
This publication has 39 references indexed in Scilit:
- The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor CellsFrontiers in Oncology, 2013
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationCancer Research, 2012
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian CancerJournal of Clinical Oncology, 2010
- PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase InhibitorsCancer Research, 2010
- Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencingProceedings of the National Academy of Sciences, 2010
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The Medical Dictionary for Regulatory Activities (MedDRA)Drug Safety, 1999